Thymoma
A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed)
Drugs by status
Phase 4 trials (3)
Phase 3 trials (3)
Phase 2 trials (54)
- saracatinib
- methylprednisolone
- anlotinib
- amrubicin
- atezolizumab
- avelumab
- belinostat
- busulfan
- cixutumumab
- prednisone
- selinexor
- doxorubicin
- lapatinib
- ramucirumab
- epirubicin
- nivolumab
- iodine
- lenvatinib
- msk-2206
- regorafenib
- octreotide
- pasireotide
- pemetrexed
- milciclib
- buparlisib
- pt-112
- sunitinib
- carboplatin
- sacituzumab govitecan
- cyclosporine
- +24 more
Phase 1 trials (17)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (1)
Organization Involved with Phase 2 Indications (48)
- Celgene
- Bristol-Myers Squibb
- Roche
- Merck
- Eli Lilly
- Genentech
- Novartis
- Crolll Gmbh
- Karyopharm Therapeutics Inc
- Tiziana Life Sciences, PLC
- Xcovery
- Nerviano Medical Sciences
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- Cornell University
- Eastern Cooperative Oncology Group
- European Thoracic Oncology Platform
- Georgetown University
- GSO Global Clinical Research BV
- Indiana University
- Johns Hopkins University
- Ohio State University
- Rutgers University
- Seoul National University
- Southwest Oncology Group
- Stanford University
- University of Lausanne
- University of Milan
- University of Regensburg
- Valley Health System
- +18 more
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (1)